{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:37Z","timestamp":1793406457267,"version":"4.5.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Carbapenem-resistant\n              <jats:italic>Acinetobacter baumannii<\/jats:italic>\n              (CRAB) remains a major threat, with high mortality and limited effective treatments. Sulbactam-durlobactam has emerged as a promising therapy against CRAB. Sulbactam-durlobactam was combined with imipenem-cilastatin in a clinical trial that led to its United States Food and Drug Administration approval. However, the additive benefit of imipenem remains uncertain. In a recent study (Antimicrob Agents Chemother 69:e01627-24, 2025,\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1128\/aac.01627-24\" xlink:type=\"simple\">https:\/\/doi.org\/10.1128\/aac.01627-24<\/jats:ext-link>\n              ), Veeraraghavan and colleagues provide convincing mechanistic evidence that adding imipenem to sulbactam-durlobactam enhances bacterial killing, likely through complementary inhibition of penicillin binding proteins, leveraging the concept of target redundancy.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00121-25","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T13:01:14Z","timestamp":1741957274000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-1056","authenticated-orcid":true,"given":"Jose M.","family":"Munita","sequence":"first","affiliation":[{"name":"Instituto de Ciencias e Innovaci\u00f3n en Medicina, Facultad de Medicina Cl\u00ednica Alemana, Universidad del Desarrollo","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-6324","authenticated-orcid":true,"given":"Pranita D.","family":"Tamma","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad094"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad556"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01268-16"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2018.0283"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01680-20"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0037"},{"key":"e_1_3_1_8_2","first-page":"206","article-title":"Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin\/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter","volume":"17","author":"Mosaed R","year":"2018","unstructured":"Mosaed R, Haghighi M, Kouchak M, Miri MM, Salarian S, Shojaei S, Javadi A, Taheri S, Nazirzadeh P, Foroumand M, Sistanizad M. 2018. Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin\/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter. Iran J Pharm Res 17:206\u2013213.","journal-title":"Iran J Pharm Res"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.22037\/ijpr.2019.112466.13775"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijccm.IJCCM_302_17"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00184-6"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01027-12"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00231"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt275"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad095"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01627-24"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00312-23"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00987.x"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit050"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2954-2958.2005"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00361-18"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.1984"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.468"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit052"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa021"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku568"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00821-20"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.08.021"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1916-6"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00121-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00121-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:33:42Z","timestamp":1743744822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00121-25"}},"subtitle":[],"editor":[{"given":"Cesar A.","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,2]]}},"alternative-id":["10.1128\/aac.00121-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00121-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"2025-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00121-25"}}